Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 8/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31751977 | 0.82 | GABRA1 (0.46) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL11967099 | 0.82 | GABRA1 (0.46) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL18753207 | 0.82 | IDO1 (0.41) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL724189 | 0.80 | P2RX7 (0.41) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL4550354 | 0.80 | MAOB (0.45) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL737569 | 0.80 | PDCD1 (0.48) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30513592 | 0.80 | P2RX7 (0.41) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL121915 | 0.79 | IDO1 (0.55) | IDO1SLC6A2SLC6A4KDM4EATM | |
| SCHEMBL29560223 | 0.79 | IDO1 (0.55) | IDO1SLC6A2SLC6A4KDM4EATM | |
| Hydrochloric Acid SCHEMBL2577850 | 0.78 | MAOB (0.47) | P2RX7IDO1CYP2D6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472160-B1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-19 | — | — | US | disclosed |
| CN-107108634-B | Imidazopyridazine derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-107108633-B | Heterocyclyl-linked imidazopyridazine derivatives as PI3K β inhibitors | 詹森药业有限公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3233839-B1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-25 | — | — | EP | disclosed |
| EP-3233862-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-03 | — | — | EP | disclosed |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| EP-3472160-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2019-04-24 | — | — | EP | disclosed |
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| CN-109311875-A | Two ring pyridines, two ring pyrazines and bicyclic pyrimidine derivatives as PI3K beta inhibitor | 詹森药业有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-10087187-B2 | Imidazopyridazine derivatives as PI3KB inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN-CILAG (FR) | 2018-03-01 | — | — | US | disclosed |
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-04 | — | — | US | disclosed |
| WO-2017216292-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | WO | disclosed |
| EP-3233839-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | Janssen Pharmaceutica NV (BE) | 2017-10-25 | — | — | EP | disclosed |
| EP-3233862-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS 3 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2017-10-25 | — | — | EP | disclosed |
| CN-107108633-A | The Imidazopyridazine derivative connected as the heterocyclic radical of PI3K beta inhibitors | 詹森药业有限公司 | 2017-08-29 | — | — | CN | disclosed |
| CN-107108634-A | Imidazopyridazine derivatives as PI3K beta inhibitors | 詹森药业有限公司 | 2017-08-29 | — | — | CN | disclosed |
| WO-2016097359-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097347-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894793-B2 | Bicyclic pyridine, pyrazine, and pyrimidine derivatives as PI3K beta inhibitors | PIK3CA, PIK3CD, PIK3CB | P2RX7 39/4885IDO1 824/4885CYP2D6 1093/4885 |
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | PIK3CB, PIK3CD, PIK3CA | P2RX7 384/4885IDO1 1131/4885CYP2D6 741/4885 |
| US-20180002336-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | P2RX7 349/4885IDO1 686/4885CYP2D6 402/4885 |
| US-20190169199-A1 | BICYCLIC PYRIDINE, PYRAZINE, AND PYRIMIDINE DERIVATIVES AS PI3K BETA INHIBITORS | PIK3CA, PIK3CD, PIK3CB | P2RX7 39/4885IDO1 824/4885CYP2D6 1093/4885 |
| US-10087187-B2 | Imidazopyridazine derivatives as PI3KB inhibitors | PIK3CB, PIK3CD, PIK3CA | P2RX7 349/4885IDO1 686/4885CYP2D6 402/4885 |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | P2RX7 384/4885IDO1 1131/4885CYP2D6 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.